These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Koch RO; Graziadei IW; Schulz F; Nachbaur K; Königsrainer A; Margreiter R; Vogel W Transpl Int; 2004 Oct; 17(9):518-24. PubMed ID: 15365603 [TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Flechner SM; Kobashigawa J; Klintmalm G Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899 [TBL] [Abstract][Full Text] [Related]
7. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140 [TBL] [Abstract][Full Text] [Related]
8. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol. Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598 [TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Stoves J; Newstead CG; Baczkowski AJ; Owens G; Paraoan M; Hammad AQ Nephrol Dial Transplant; 2004 Aug; 19(8):2113-20. PubMed ID: 15161956 [TBL] [Abstract][Full Text] [Related]
10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [TBL] [Abstract][Full Text] [Related]
11. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352 [TBL] [Abstract][Full Text] [Related]
12. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Pascual J; Quereda C; Zamora J; Hernández D; Transplant Proc; 2005 Nov; 37(9):3746-8. PubMed ID: 16386525 [TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Höcker B; Tönshoff B Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600 [TBL] [Abstract][Full Text] [Related]
14. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology. Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152 [TBL] [Abstract][Full Text] [Related]
15. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Boyer O; Le Bidois J; Dechaux M; Gubler MC; Niaudet P Transplantation; 2005 May; 79(10):1405-10. PubMed ID: 15912111 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759 [TBL] [Abstract][Full Text] [Related]
17. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Bakker RC; Hollander AA; Mallat MJ; Bruijn JA; Paul LC; de Fijter JW Kidney Int; 2003 Sep; 64(3):1027-34. PubMed ID: 12911553 [TBL] [Abstract][Full Text] [Related]
18. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience. Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197 [TBL] [Abstract][Full Text] [Related]
19. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J Transplantation; 2004 Jan; 77(2):252-8. PubMed ID: 14742990 [TBL] [Abstract][Full Text] [Related]
20. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Suwelack B; Gerhardt U; Hohage H Am J Transplant; 2004 Apr; 4(4):655-62. PubMed ID: 15023160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]